4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The majority of breast cancers (BCs) expressing estrogen receptor (ER) have shown endocrine resistance. Our previous study demonstrated that ferredoxin reductase (FDXR) promoted mitochondrial function and ER+ breast tumorigenesis. But the underlying mechanism is not clear.

          Methods

          Liquid chromatography (LC) tandem mass spectrometry (MS/MS)-based metabolite profiling was utilized to reveal the metabolites regulated by FDXR. RNA microarray was utilized to determine the potential downstream targets of FDXR. Seahorse XF24 analyzer was performed to analyze the FAO-mediated oxygen consumption rate (OCR). Q-PCR and western blotting assays were used to measure expression levels of FDXR and CPT1A. MTS, 2D colony formation and anchorage-independent growth assays were used to evaluate the effects of FDXR or drug treatments on tumor cell growth of primary or endocrine-resistant breast cancer cells.

          Results

          We found that depletion of FDXR inhibited fatty acid oxidation (FAO) by suppressing CPT1A expression. Endocrine treatment increased the expression levels of both FDXR and CPT1A. Further, we showed that depletion of FDXR or FAO inhibitor etomoxir treatment reduced primary and endocrine-resistant breast cancer cell growth. Therapeutically, combining endocrine therapy with FAO inhibitor etomoxir synergistically inhibits primary and endocrine-resistant breast cancer cell growth.

          Discussion

          We reveal that the FDXR-CPT1A-FAO signaling axis is essential for primary and endocrine-resistant breast cancer cell growth, thus providing a potential combinatory therapy against endocrine resistance in ER+ breast cancer.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: found

          Hallmarks of Cancer: The Next Generation

          The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Emerging Hallmarks of Cancer Metabolism.

            Tumorigenesis is dependent on the reprogramming of cellular metabolism as both direct and indirect consequence of oncogenic mutations. A common feature of cancer cell metabolism is the ability to acquire necessary nutrients from a frequently nutrient-poor environment and utilize these nutrients to both maintain viability and build new biomass. The alterations in intracellular and extracellular metabolites that can accompany cancer-associated metabolic reprogramming have profound effects on gene expression, cellular differentiation, and the tumor microenvironment. In this Perspective, we have organized known cancer-associated metabolic changes into six hallmarks: (1) deregulated uptake of glucose and amino acids, (2) use of opportunistic modes of nutrient acquisition, (3) use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production, (4) increased demand for nitrogen, (5) alterations in metabolite-driven gene regulation, and (6) metabolic interactions with the microenvironment. While few tumors display all six hallmarks, most display several. The specific hallmarks exhibited by an individual tumor may ultimately contribute to better tumor classification and aid in directing treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Understanding the Intersections between Metabolism and Cancer Biology

              Transformed cells adapt metabolism to support tumor initiation and progression. Specific metabolic activities can participate directly in the process of transformation or support the biological processes that enable tumor growth. Exploiting cancer metabolism for clinical benefit requires defining the pathways that are limiting for cancer progression and understanding the context specificity of metabolic preferences and liabilities in malignant cells. Progress toward answering these questions is providing new insight into cancer biology and can guide the more effective targeting of metabolism to help patients.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                03 May 2023
                2023
                : 13
                : 1105117
                Affiliations
                [1] 1 Department of Thyroid and Breast Surgery, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University , Wuhan, China
                [2] 2 Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, China
                [3] 3 Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine , Chapel Hill, NC, United States
                [4] 4 Department of Pharmacology and Cancer Biology, Duke University School of Medicine , Durham, NC, United States
                [5] 5 Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX, United States
                [6] 6 Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX, United States
                Author notes

                Edited by: Chunyan Dong, Tongji University, China

                Reviewed by: Helena Chang, UCLA Health System, United States; Marcos Lopez, University of Puerto Rico, Puerto Rico; Sarrah Widatalla, Roche Diagnostics, United States

                Article
                10.3389/fonc.2023.1105117
                10189134
                37207154
                d5a2bd8b-689c-41b9-af45-3a87db156933
                Copyright © 2023 Yan, Gao, Gao, Hong, Cheng, Liu, Zhang and Zhang

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 22 November 2022
                : 19 April 2023
                Page count
                Figures: 5, Tables: 0, Equations: 0, References: 68, Pages: 12, Words: 4653
                Funding
                Funded by: Fundamental Research Funds for the Central Universities , doi 10.13039/501100012226;
                Funded by: American Cancer Society , doi 10.13039/100000048;
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Funded by: Natural Science Foundation of Hubei Province , doi 10.13039/501100003819;
                Funded by: China Postdoctoral Science Foundation , doi 10.13039/501100002858;
                This work is supported by the Fundamental Research Funds for the Central Universities 2042020kf0197 (JZ), ACS RSG-18-059-01-TBE (QZ), National Natural Science Foundation of China 31970737 (JZ) and 32100570 (CY), the Startup Funding from Wuhan University (JZ), Natural Science Foundation of Hubei Province 2020CFA071 (JZ) and the China Postdoctoral Science Foundation 2020M672408 (CY). We also sincerely thank the core facility of the Medical Research Institute at Wuhan University for their technical support.
                Categories
                Oncology
                Original Research
                Custom metadata
                Breast Cancer

                Oncology & Radiotherapy
                breast cancer,endocrine resistance,ferredoxin reductase,palmitoyltransferase 1a,fatty acid oxidation,combination therapy

                Comments

                Comment on this article